Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

June 5, 2024

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2024

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

May 13, 2024

Financial Events

Imunon’s First Quarter 2024 Financial Results

May 13, 2024 at 11:00 AM EDT

Imunon’s Fourth Quarter 2023 Financial Results

March 28, 2024 at 10:00 AM EDT